Cochrane Abstracts
Biologic or tofacitinib monotherapy for rheumatoid arthritis in people with traditional disease‐modifying anti‐rheumatic drug (DMARD) failure: a Cochrane Systematic Review and network meta‐analysis (NMA) New
Biologic or tofacitinib monotherapy for rheumatoid arthritis in people with traditional disease‐modifying anti‐rheumatic drug (DMARD) failure: a Cochrane Systematic Review and network meta‐analysis (NMA) New is a topic covered in the Cochrane Abstracts.
To view the entire topic, please log in or purchase a subscription.
Evidence Central is an integrated web and mobile solution that helps clinicians quickly answer etiology, diagnosis, treatment, and prognosis questions using the latest evidence-based research. Explore these free sample topics:
There's more to see -- the rest of this entry is available only to subscribers.
Citation
"Biologic or Tofacitinib Monotherapy for Rheumatoid Arthritis in People With Traditional Disease‐modifying Anti‐rheumatic Drug (DMARD) Failure: a Cochrane Systematic Review and Network Meta‐analysis (NMA) New." Cochrane Abstracts, Evidence Central, evidence.unboundmedicine.com/evidence/view/Cochrane/438198/0/Biologic_or_tofacitinib_monotherapy_for_rheumatoid_arthritis_in_people_with_traditional_disease‐modifying_anti‐rheumatic_drug__DMARD__failure:_a_Cochrane_Systematic_Review_and_network_meta‐analysis__NMA__New. Accessed 15 January 2021.
Biologic or tofacitinib monotherapy for rheumatoid arthritis in people with traditional disease‐modifying anti‐rheumatic drug (DMARD) failure: a Cochrane Systematic Review and network meta‐analysis (NMA) New. Cochrane Abstracts. https://evidence.unboundmedicine.com/evidence/view/Cochrane/438198/0/Biologic_or_tofacitinib_monotherapy_for_rheumatoid_arthritis_in_people_with_traditional_disease‐modifying_anti‐rheumatic_drug__DMARD__failure:_a_Cochrane_Systematic_Review_and_network_meta‐analysis__NMA__New. Accessed January 15, 2021.
Biologic or tofacitinib monotherapy for rheumatoid arthritis in people with traditional disease‐modifying anti‐rheumatic drug (DMARD) failure: a Cochrane Systematic Review and network meta‐analysis (NMA) New. In Cochrane Abstracts Retrieved January 15, 2021, from https://evidence.unboundmedicine.com/evidence/view/Cochrane/438198/0/Biologic_or_tofacitinib_monotherapy_for_rheumatoid_arthritis_in_people_with_traditional_disease‐modifying_anti‐rheumatic_drug__DMARD__failure:_a_Cochrane_Systematic_Review_and_network_meta‐analysis__NMA__New
Biologic or Tofacitinib Monotherapy for Rheumatoid Arthritis in People With Traditional Disease‐modifying Anti‐rheumatic Drug (DMARD) Failure: a Cochrane Systematic Review and Network Meta‐analysis (NMA) New [Internet]. In: Cochrane Abstracts. [cited 2021 January 15]. Available from: https://evidence.unboundmedicine.com/evidence/view/Cochrane/438198/0/Biologic_or_tofacitinib_monotherapy_for_rheumatoid_arthritis_in_people_with_traditional_disease‐modifying_anti‐rheumatic_drug__DMARD__failure:_a_Cochrane_Systematic_Review_and_network_meta‐analysis__NMA__New.
* Article titles in AMA citation format should be in sentence-case
TY - ELEC
T1 - Biologic or tofacitinib monotherapy for rheumatoid arthritis in people with traditional disease‐modifying anti‐rheumatic drug (DMARD) failure: a Cochrane Systematic Review and network meta‐analysis (NMA) New
ID - 438198
BT - Cochrane Abstracts
UR - https://evidence.unboundmedicine.com/evidence/view/Cochrane/438198/0/Biologic_or_tofacitinib_monotherapy_for_rheumatoid_arthritis_in_people_with_traditional_disease‐modifying_anti‐rheumatic_drug__DMARD__failure:_a_Cochrane_Systematic_Review_and_network_meta‐analysis__NMA__New
DB - Evidence Central
DP - Unbound Medicine
ER -
